<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Erythromycin (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Erythromycin (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Erythromycin (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11672" href="/d/html/11672.html" rel="external">see "Erythromycin (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="15977" href="/d/html/15977.html" rel="external">see "Erythromycin (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8086256"><span class="drugH1">Brand Names: US</span>
<ul>
<li>E.E.S. 400;</li>
<li>E.E.S. Granules;</li>
<li>Ery-Tab;</li>
<li>EryPed 200;</li>
<li>EryPed 400;</li>
<li>Erythrocin Lactobionate;</li>
<li>Erythrocin Stearate</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871080"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Eryc [DSC];</li>
<li>Erythro-Base;</li>
<li>Erythro-S [DSC];</li>
<li>Erythrocin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8089967"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Macrolide</li></ul></div>
<div class="block doa drugH1Div" id="F8086406"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>PCE tablets have been discontinued in the United States for &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Due to differences in absorption, 400 mg erythromycin ethylsuccinate produces the same serum levels as 250 mg erythromycin base or stearate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Base or stearate: 250 to 500 mg every 6 to 12 hours; maximum: 4 g daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Ethylsuccinate: 400 to 800 mg every 6 to 12 hours; maximum: 4 g daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Lactobionate: 15 to 20 mg/kg/day divided every 6 hours or 500 mg to 1 g every 6 hours; maximum: 4 g daily.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5c4354e0-2178-427d-a042-9beb609e2523">Acne vulgaris, inflammatory, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris, inflammatory, moderate to severe (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use in combination with topical acne therapy. Reserve for patients who cannot use preferred agents; use may be limited by bacterial resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 250 to 500 mg (base) twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Graber.1','lexi-content-ref-15794732','lexi-content-ref-12688836']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Graber.1','lexi-content-ref-15794732','lexi-content-ref-12688836'])">Ref</a></span>). Treatment should ideally be limited to 3 to 4 months to minimize the risk of resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="452a5fca-911d-417a-b625-1b0f7a95ccab">
<i>Bartonella</i> spp. infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Bartonella</b></i>
<b>spp. infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b> Patients with HIV:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment: </i>
<b>Note:</b> Duration of therapy is ≥3 months; continuation of therapy depends on clinical condition and response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Bacillary angiomatosis, cat scratch disease, peliosis hepatis, bacteremia, and osteomyelitis: <b>Oral, IV:</b> 500 mg every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Other severe infections (excluding CNS infections or endocarditis): <b>Oral, IV:</b> 500 mg every 6 hours in combination with rifampin; IV therapy may be needed initially (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Suppressive therapy:</i>
<b>Note:</b> For patients who experience a relapse after receiving a ≥3-month course of primary treatment. <b>Oral:</b> 500 mg every 6 hours. Continue until patient has received ≥3 months of therapy and CD4 count is &gt;200 cells/mm<sup>3</sup> for ≥6 months; some experts discontinue therapy only if Bartonella titers have also decreased 4-fold (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Patients without HIV:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">Bacillary angiomatosis (BA), peliosis hepatitis (PH): <b>Oral:</b> 500 mg (base) 4 times daily for 3 months (BA) or 4 months (PH) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1435899','lexi-content-ref-15155180','lexi-content-ref-24973422','lexi-content-ref-8430982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1435899','lexi-content-ref-15155180','lexi-content-ref-24973422','lexi-content-ref-8430982'])">Ref</a></span>). <b>Note:</b> IDSA skin and soft tissue infection guidelines recommend a duration of initial therapy of 2 weeks to 2 months for cutaneous BA, although treatment durations are not standardized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="816318ee-927a-4bf7-8350-4ac96db9152a">Chronic obstructive pulmonary disease, prevention of exacerbations</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease (COPD), prevention of exacerbations (off-label use):</b>
<b>Oral:</b> 200 to 400 mg/day (formulation not specified) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11555501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11555501'])">Ref</a></span>) or 250 mg (stearate) twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18723437']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18723437'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da00ba7a-69cf-4013-8c0f-97034d028388">Endoscopy/esophagogastroduodenoscopy, adjunctive prokinetic agent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endoscopy/esophagogastroduodenoscopy, adjunctive prokinetic agent (off-label use): IV:</b> 250 mg as a single dose infused over 20 to 30 minutes; perform endoscopy 20 to 90 minutes after infusion is complete (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929377','lexi-content-ref-16771939','lexi-content-ref-33567467','lexi-content-ref-12105828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929377','lexi-content-ref-16771939','lexi-content-ref-33567467','lexi-content-ref-12105828'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="66be8ee3-7feb-4967-967f-aa5c4784bf19">Gastroparesis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroparesis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 3 mg/kg administered over 45 minutes every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23147521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23147521'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Patients refractory/intolerant to other prokinetic agents (eg, metoclopramide, domperidone): 250 to 500 mg (base) 3 times daily before meals. Limit duration of therapy, tachyphylaxis may occur after 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23147521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23147521'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae778312-2b20-4267-bf81-b1227062d540">Legionnaire disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Legionnaire disease: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 to 4 g/day in divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 1.6 to 4 g (ethylsuccinate) daily or 1 to 4 g (base or stearate) daily in divided doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c43d016-c199-4561-bd12-4713812696da">Pertussis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pertussis:</b>
<b>Oral:</b> 500 mg (base) every 6 hours for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16340941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16340941'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="531f1b7e-8e3a-4f42-b698-d0039dd5e8b2">Rheumatic fever, secondary prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatic fever, secondary prophylaxis (alternative agent): Oral:</b> 250 mg (base or stearate) or 400 mg (ethylsuccinate) twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8597b7bf-d38b-46ed-ae30-27103563bc5c">Sexually transmitted infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sexually transmitted infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chancroid (off-label use):</i>
<b>Oral:</b> 500 mg (base) 3 times daily for 7 days; <b>Note:</b> Isolates with intermediate resistance have been documented (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Granuloma inguinale (donovanosis) (alternative agent) (off-label use):</i>
<b>Oral:</b> 500 mg (base) 4 times daily for &gt;3 weeks and until resolution of lesions. <b>Note:</b> If symptoms do not improve within the first few days of therapy, the addition of a second agent may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lymphogranuloma venereum (alternative agent) (off-label use):</i>
<b>Oral:</b> 500 mg (base) 4 times daily for 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical (preoperative) prophylaxis (colorectal) (off-label dose):</b>
<b>Oral:</b> 1 g erythromycin base per dose at 1 PM, 2 PM, and 11 PM on the day before 8 AM surgery combined with mechanical cleansing of the large intestine, oral neomycin. Perioperative IV antibiotics are also given on the day of surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991375"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥15 mL/minute/1.73 m<sup>2</sup>: <b>Oral, IV:</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3781679','lexi-content-ref-14412751','lexi-content-ref-671237','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3781679','lexi-content-ref-14412751','lexi-content-ref-671237','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: <b>Oral, IV:</b> Increased incidence of ototoxicity (a concentration-dependent adverse effect) in patients with severe kidney impairment has been reported. Consider limiting erythromycin dose to 2 g/day or using an alternative agent; monitor hearing acuity closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6860057','lexi-content-ref-25859365','lexi-content-ref-Nagata.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6860057','lexi-content-ref-25859365','lexi-content-ref-Nagata.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7151848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7151848'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV</b>
<b>:</b> Increased incidence of ototoxicity (a concentration-dependent adverse effect) in patients with severe kidney impairment has been reported. Consider limiting erythromycin dose to 2 g/day or using an alternative agent; monitor hearing acuity closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3494560','lexi-content-ref-6860057','lexi-content-ref-25859365','lexi-content-ref-Nagata.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3494560','lexi-content-ref-6860057','lexi-content-ref-25859365','lexi-content-ref-Nagata.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not likely to be significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV</b>
<b>:</b> Increased incidence of ototoxicity (a concentration-dependent adverse effect) in patients with severe kidney impairment has been reported. Consider limiting erythromycin dose to 2 g/day or using an alternative agent; monitor hearing acuity closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25859365','lexi-content-ref-Nagata.1','lexi-content-ref-6117714','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25859365','lexi-content-ref-Nagata.1','lexi-content-ref-6117714','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b>
<b>Oral, IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b>
<b>Oral, IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988377"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doe drugH1Div" id="F8086407"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F8086405"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="15977" href="/d/html/15977.html" rel="external">see "Erythromycin (systemic): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Erythromycin is available in an IV formulation as the lactobionate salt, and orally as base, ethylsuccinate salt, or stearate salt. In adults, 400 mg erythromycin ethylsuccinate produces the same concentrations as 250 mg of erythromycin base or stearate; however, in pediatric patients, weight-based dosing is typically used interchangeably.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Base, ethylsuccinate, stearate: 40 to 50 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 4,000 mg/<b>day</b>; the manufacturer's labeling also describes dividing the daily dose every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Lactobionate: 15 to 20 mg/kg/day divided every 6 hours; maximum daily dose: 4,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce2c669f-3aef-42bf-815c-cd8f32908ea9">Acne vulgaris, moderate to severe, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris, moderate to severe, treatment (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use in combination with topical acne therapy. Reserve use for patients &lt;8 years of age or with allergies who cannot receive tetracyclines; use limited by bacterial resistance and adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-23637225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-23637225'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: 250 to 500 mg 1 to 2 times daily; maximum daily dose: 50 mg/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23637225','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23637225','lexi-content-ref-manu.1'])">Ref</a></span>). Treatment should ideally be limited to 3 to 4 months to minimize development of resistance; some experts suggest discontinuation or tapering within 1 to 2 months once new lesions have stopped emerging; consistent follow-up and reevaluation is recommended for patients who require a longer course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-23637225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-23637225'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="452a5fca-911d-417a-b625-1b0f7a95ccab">
<i>Bartonella</i> spp. infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Bartonella</b></i>
<b> spp. infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (bacillary angiomatosis, peliosis hepatitis):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Oral: Ethylsuccinate: 10 mg/kg/dose every 6 hours; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-15155180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-15155180'])">Ref</a></span>). <b>Note:</b> In adolescent patients with HIV and multifocal disease or with clinical decompensation, give in combination with rifampin; IV therapy may be needed initially.</p>
<p style="text-indent:-2em;margin-left:6em;">Duration of treatment:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients without HIV</i>: For bacillary angiomatosis, treat for 3 months; for peliosis hepatitis, treat for 4 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15155180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15155180'])">Ref</a></span>). For cutaneous bacillary angiomatosis, IDSA skin and soft tissue infection guidelines recommend a duration of initial therapy of 2 weeks to 2 months, although treatment durations are not standardized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients with HIV</i>: Duration of therapy is ≥3 months; continuation of therapy depends on clinical condition and response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-15155180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-15155180'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Suppressive therapy for patients with HIV who experience a relapse after receiving a ≥3-month course of primary treatment:</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 500 mg every 6 hours. Continue until patient has received at least 3 to 4 months of therapy and CD4 count is &gt;200 cells/mm<sup>3 </sup>for ≥6 months; some experts discontinue therapy only if <i>Bartonella</i> titers have also decreased 4-fold (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6e2a56fe-ae38-44c3-9cbe-f0cf191e8b37">Chancroid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chancroid (<i>Haemophilus ducreyi</i>):</b> Limited data available: Children ≥45 kg and Adolescents: Base: Oral: 500 mg every 8 hours for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f392581d-56e1-49fb-b3b8-a966080e7091">
<i>Chlamydia trachomatis</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Chlamydia trachomatis</i> infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children weighing &lt;45 kg: Oral: Base, ethylsuccinate: 12.5 mg/kg/dose every 6 hours for 14 days; maximum dose: 500 mg/dose. In infants with pneumonia, a second course may be necessary due to efficacy of ~80% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Lymphogranuloma venereum: Oral: Base: 500 mg 4 times daily for 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9938d465-584f-48f7-8083-e90bc984c47e">Exit-site or tunnel infection, peritoneal dialysis catheter</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exit-site or tunnel infection, peritoneal dialysis catheter:</b> Infants, Children, and Adolescents: Oral: Base: 30 to 50 mg/kg/<b>day</b> divided every 6 to 8 hours; maximum dose: 500 mg/dose. Exit-site infection should be treated for ≥2 weeks and for at least 7 days after complete resolution, or for ≥3 weeks for <i>Staphylococcus aureus</i>; tunnel infection should be treated for 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c979d2e-5a65-49c3-9d94-716d40381c66">Gastroparesis or prokinetic agent for GI motility</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroparesis or prokinetic agent for GI motility:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Response determination during gastric emptying study</i>: IV: 2.8 mg/kg infused over 20 minutes; maximum dose: 250 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22314391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22314391'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment:</i> Oral: 3 mg/kg/dose 4 times daily; may increase as needed to effect up to 10 mg/kg/dose; maximum dose: 250 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22228004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22228004'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c00357b8-de45-4183-8d7b-6cc88f991ddf">Impetigo</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Impetigo (alternative agent):</b> Infants, Children, and Adolescents: Oral: Base, ethylsuccinate: 40 mg/kg/<b>day</b> divided every 6 to 8 hours for 7 days; maximum dose (base): 250 mg/dose; maximum dose (ethylsuccinate): 400 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e096d904-52ea-4eb0-a6d7-1e796cc45b21">Lyme disease, erythema migrans</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lyme disease (<i>Borrelia </i>spp. infection), erythema migrans (alternative agent):</b> Limited data available: <b>Note:</b> Current guidelines recommend macrolides (azithromycin) only when first-line agents cannot be used due to lower efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 12.5 mg/kg/dose every 6 hours for 14 to 21 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17029130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17029130'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f573e1c-a236-4e93-a9e3-ccd522d76fbf">Pertussis, treatment or postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pertussis, treatment or postexposure prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Most commonly reported salt forms in studies were erythromycin ethylsuccinate or base (when reported) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16340941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16340941'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;6 months: Oral: 10 to 12.5 mg/kg/dose every 6 hours for 14 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16340941','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16340941','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children: Oral: 10 to 12.5 mg/kg/dose every 6 hours for 7 to 14 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16340941','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16340941','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 500 mg every 6 hours for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49c475fc-880a-40d8-89c0-b873705addcd">Pneumococcal prophylaxis in patients with sickle cell disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumococcal prophylaxis in patients with sickle cell disease (alternative agent for penicillin allergy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥4 months and Children &lt;3 years: Oral: 125 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11148514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11148514'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 3 to &lt;5 years: Oral: 250 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11148514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11148514'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="467ff846-caab-45eb-ab98-b658425d6884">Pneumonia, atypical, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, atypical, community-acquired (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;3 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild infection or step-down therapy: Oral: 10 mg/kg/dose every 6 hours; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe infection: IV: Lactobionate: 5 mg/kg/dose every 6 hours; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d38075e1-39f4-4a72-9e69-c27c9fca2398">Surgical prophylaxis, colorectal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis, colorectal:</b> Limited data available: Children and Adolescents: Oral: Base: 20 mg/kg/dose for 3 doses; administer at 1 PM, 2 PM, and 11 PM on the day before surgery, in combination with mechanical cleansing of the large intestine and oral neomycin; maximum dose: 1,000 mg/dose; perioperative IV antibiotics should also be administered on the day of surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51108710"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: The following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). <b>Note:</b> Renally adjusted dose recommendations are based on oral doses of 30 to 50 mg/kg/<b>day</b> divided every 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR ≥10 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Intermittent hemodialysis, peritoneal dialysis: Not removed by peritoneal dialysis or hemodialysis: Oral: 10 to 17 mg/kg/dose every 8 hours.</p></div>
<div class="block dohp drugH1Div" id="F51108711"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F8086284"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined. Incidence may vary with formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: QT<sub>c</sub> prolongation, torsade de pointes, ventricular arrhythmia, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Seizure</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Erythema multiforme, pruritus, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea, oral candidiasis, pancreatitis, pseudomembranous colitis, pyloric stenosis (infantile hypertrophic), vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Abnormal hepatic function tests, cholestatic jaundice (most common with estolate), hepatitis</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Injection site phlebitis</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Otic: Hearing loss</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Interstitial nephritis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing and/or case reports: Hepatotoxicity (idiosyncratic) (Chalasani 2014)</p></div>
<div class="block coi drugH1Div" id="F8086273"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to erythromycin, any macrolide antibiotics, or any component of the formulation; concomitant use with astemizole, cisapride, dihydroergotamine, ergotamine, lovastatin, pimozide, simvastatin, or terfenadine.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Injection: History of QT prolongation (acquired or congenital); ventricular cardiac arrhythmia, including torsades de pointes; electrolyte imbalance (hypokalemia, hypomagnesemia); IV bolus/push.</p></div>
<div class="block war drugH1Div" id="F8086274"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered cardiac conduction: Macrolides have been associated with rare QTc prolongation and ventricular arrhythmias, including torsade de pointes; use with caution in patients at risk of prolonged cardiac repolarization; avoid use in patients with prolonged QT interval, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or concurrent use of Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, dofetilide, sotalol) antiarrhythmic agents.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with preexisting liver disease; hepatic impairment, including hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been observed. Discontinue if symptoms of malaise, nausea, vomiting, abdominal colic, and fever.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Exacerbation of and new onset of myasthenia gravis symptoms have been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Major inhibitor of CYP3A4: Use caution with any agents with substantial metabolism through the CYP3A4 pathway; high potential for drug interactions exists. Avoid concurrent use with strong CYP3A4 inhibitors; may increase the risk of sudden cardiac death (Ray 2004).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: May be at increased risk of adverse events, including hearing loss and/or torsade de pointes, particularly if concurrent renal/hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage form specific issues:</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878702"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Infantile hypertrophic pyloric stenosis (IHPS) has been associated with erythromycin use in the first 6 weeks of life, with the highest risk occurring in the first 2 weeks of life (Abdellatif 2019; Cooper 2002; Eberly 2015; <i>Red Book</i> [AAP 2021]). Absolute risk varies; in a large retrospective study using a health system database, &lt;1% of neonates and infants &lt;90 days of age who were prescribed erythromycin developed IHPS, though this reflected an ~4-fold increased risk as compared to patients who did not receive erythromycin. Neonates and infants &lt;14 days of age at time of exposure were ~13 times more likely to experience IHPS (Eberly 2015). In a retrospective study in neonates receiving erythromycin prophylaxis for pertussis, risk of IHPS was 5.1% in neonates receiving &lt;1 week of erythromycin and 10% in neonates who received &gt;14 days of erythromycin (Honein 1999). Risk appears to be increased with use within the first 2 weeks of life, in patients born at term (vs preterm), with longer duration of therapy (&gt;14 days), or with higher doses (~40 mg/kg/day) (Abdellatif 2019; Eberly 2015; Ericson 2015; Honein 1999; Hussain 2002; Maheshwai 2007). Pyloromyotomy for IHPS was undertaken a median of 13 days (range: 2 to 40 days; IQR: 8 to 25 days) after erythromycin exposure in a large database study (Eberly 2015). Carefully evaluate risks and benefits of treatment with erythromycin before use in neonates and young infants and monitor closely (<i>Red Book</i> [AAP 2021]; manufacturer's labeling).</p></div>
<div class="block prod-avail drugH1Div" id="F53299745"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">PCE tablets have been discontinued in the US for more than 1 year.</p></div>
<div class="block foc drugH1Div" id="F8086458"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release Particles, Oral, as base: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as lactobionate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Erythrocin Lactobionate: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral, as ethylsuccinate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">E.E.S. Granules: 200 mg/5 mL (100 mL, 200 mL) [cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EryPed 200: 200 mg/5 mL (100 mL) [fruit flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EryPed 400: 400 mg/5 mL (100 mL) [banana flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/5 mL (100 mL, 200 mL); 400 mg/5 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral, as ethylsuccinate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/5 mL (100 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as base: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as ethylsuccinate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">E.E.S. 400: 400 mg [contains corn starch, fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as stearate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Erythrocin Stearate: 250 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as base: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ery-Tab: 250 mg, 333 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 333 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F8086259"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F8086461"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, enteric pellets</b> (Erythromycin Base Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $9.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Erythrocin Lactobionate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $101.45</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Erythromycin Lactobionate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $240.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (E.E.S. Granules Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/5 mL (per mL): $4.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (EryPed 200 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/5 mL (per mL): $4.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (EryPed 400 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg/5 mL (per mL): $7.94</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Erythromycin Ethylsuccinate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/5 mL (per mL): $3.91 - $4.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg/5 mL (per mL): $7.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Ery-Tab Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $10.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">333 mg (per each): $12.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $15.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Erythromycin Base Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $8.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">333 mg (per each): $10.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $13.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (E.E.S. 400 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $14.61</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Erythrocin Stearate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $13.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Erythromycin Base Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $12.46 - $13.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $18.79 - $20.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Erythromycin Ethylsuccinate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $14.61</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871081"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release Particles, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eryc: 333 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release Particles, Oral, as base: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eryc: 250 mg [DSC] [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as lactobionate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Erythrocin: 500 mg (1 ea); 1000 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as base: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as stearate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg [DSC]</p></div>
<div class="block adm drugH1Div" id="F8086411"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer base, PCE, or stearate dosage forms on an empty stomach (2 hours before or after a meal); administer ethylsuccinate (EES) or delayed release (ERY-TAB) without regard to meals; may consider administering after food to decrease GI discomfort. Swallow delayed-release capsule or enteric-coated tablets whole; do not chew or break.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Capsule and tablet, delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Delayed-release capsule and tablet cannot be opened. Switch to IR tablet or oral suspension.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse 1 g over 20 to 60 minutes. For pre-endoscopy/esophagogastroduodenoscopy, infuse 250 mg over 20 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929377'])">Ref</a></span>). IV infusion may be very irritating to the vein; infusion should be sufficiently slow to minimize pain along the vein; diluted infusions must be completed in ≤8 hours. Do not administer IV push or bolus.</p></div>
<div class="block admp drugH1Div" id="F52614200"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer base or stearate dosage forms on an empty stomach (at least 30 minutes and preferably 2 hours before a meal). Administer ethylsuccinate (EES) or delayed-release (ERY-TAB) without regards to meals; may consider administering after food to decrease GI discomfort. Swallow delayed-release capsule or enteric-coated tablets whole, do not chew or break. Shake reconstituted suspension well before use.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer by intermittent IV infusion over 20 to 60 minutes or as a continuous infusion. Intermittent IV infusion may be very irritating to the vein; per the manufacturer, continuous infusion is preferable due to slower infusion rate and lower concentration. For intermittent IV infusion, prolonging the infusion duration over 60 minutes or longer has been recommended to decrease the cardiotoxic effects of erythromycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8018130','lexi-content-ref-8190550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8018130','lexi-content-ref-8190550'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F8086260"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial infections:</b> Treatment of susceptible bacterial infections, including <i>Streptococcus pyogenes</i>, some <i>Streptococcus pneumoniae,</i> some <i>Staphylococcus aureus</i>, <i>Mycoplasma pneumoniae</i>, <i>Legionella pneumophila</i>, diphtheria, pertussis, <i>Chlamydia</i> and erythrasma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical (preoperative) prophylaxis (colorectal):</b> Colorectal decontamination, in conjunction with other agents, prior to surgical intervention</p></div>
<div class="block off-label drugH1Div" id="F25473832"><span class="drugH1">Use: Off-Label: Adult</span><p>Acne vulgaris, inflammatory, moderate to severe; Bartonella spp. infections; Chancroid; Chronic obstructive pulmonary disease, prevention of exacerbations; Endoscopy/esophagogastroduodenoscopy, adjunctive prokinetic agent; Gastroparesis (management); Granuloma inguinale (donovanosis); Lymphogranuloma venereum</p></div>
<div class="block mst drugH1Div" id="F8085309"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Erythromycin may be confused with azithromycin, clarithromycin</p>
<p style="text-indent:-2em;margin-left:4em;">Eryc may be confused with Emcyt, Ery-Tab</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Erythromycin (systemic), when used in neonates, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of hypertrophic pyloric stenosis unless treating <i>Chlamydia trachomatis </i>pneumonia (strong recommendation; high quality of evidence)<i></i>(PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F8086288"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2B6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (moderate), P-glycoprotein/ABCB1</p></div>
<div class="block dri drugH1Div" id="F8086289"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib.  Management: Monitor for increased abemaciclib toxicities if combined with moderate CYP3A4 inhibitors. Consider reducing the abemaciclib dose in 50 mg decrements if necessary.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib.  Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALfentanil.  Management: If use of alfentanil and moderate CYP3A4 inhibitors is necessary, consider dosage reduction of alfentanil until stable drug effects are achieved. Frequently monitor patients for respiratory depression and sedation when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alfuzosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alitretinoin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alitretinoin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALPRAZolam.  Management: Consider alternatives to this combination when possible. If combined, consider an alprazolam dose reduction and monitor for increased alprazolam effects and toxicities (eg, sedation, lethargy).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the QTc-prolonging effect of Erythromycin (Systemic). Erythromycin (Systemic) may enhance the QTc-prolonging effect of Amiodarone. Erythromycin (Systemic) may increase the serum concentration of Amiodarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Astemizole: May enhance the QTc-prolonging effect of Erythromycin (Systemic). Erythromycin (Systemic) may enhance the QTc-prolonging effect of Astemizole. Erythromycin (Systemic) may increase the serum concentration of Astemizole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atogepant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avacopan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor. Patients receiving such a combination should also be monitored more closely for evidence of adverse effects (eg, hypotension, syncope, priapism).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avapritinib.  Management: Avoid use of moderate CYP3A4 inhibitors with avapritinib. If this combination cannot be avoided, reduce the avapritinib dose to 100 mg daily for the treatment of GIST or to 50 mg daily for the treatment of advanced systemic mastocytosis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Axitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: Erythromycin (Systemic) may increase the serum concentration of Barnidipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with P-glycoprotein (P-gp) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inhibitors when possible. If such a combination cannot be avoided, reduce the dose of brigatinib by approximately 40% (ie, from 180 mg to 120 mg, from 120 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine.  Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor. The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic).  Management: Avoid the concomitant use of CYP3A4 inhibitors and oral budesonide. If patients receive both budesonide and CYP3A4 inhibitors, they should be closely monitored for signs and symptoms of corticosteroid excess.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: Erythromycin (Systemic) may increase the serum concentration of BusPIRone.  Management: Limit the buspirone dose to 2.5 mg twice daily and monitor for increased buspirone effects/toxicities if combined with erythromycin. Dose adjustments of buspirone or erythromycin should be based on clinical assessments.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers (Nondihydropyridine): Erythromycin (Systemic) may increase the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Erythromycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Capivasertib.  Management: If capivasertib is combined with moderate CYP3A4 inhibitors, reduce the capivasertib dose to 320 mg twice daily for 4 days, followed by 3 days off. Monitor patients closely for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Cariprazine. Specifically, concentrations of didesmethylcariprazine (DDCAR), the primary active metabolite of cariprazine, may increase. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cariprazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: May enhance the QTc-prolonging effect of Erythromycin (Systemic). Ceritinib may increase the serum concentration of Erythromycin (Systemic). Erythromycin (Systemic) may increase the serum concentration of Ceritinib. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Erythromycin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: May enhance the QTc-prolonging effect of Erythromycin (Systemic). Erythromycin (Systemic) may enhance the QTc-prolonging effect of Cisapride. Erythromycin (Systemic) may increase the serum concentration of Cisapride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Citalopram.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Topical): Erythromycin (Systemic) may diminish the therapeutic effect of Clindamycin (Topical).  Management: Consider avoiding the concomitant use of systemic erythromycin and topical clindamycin when treating acne vulgaris. This recommendation does not appear to apply to intravaginal use of clindamycin for the treatment of bacterial vaginosis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Erythromycin (Systemic) may diminish the antiplatelet effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Erythromycin (Systemic). Management: Consider alternatives to this combination when cobicistat is combined with atazanavir or darunavir. If combined, monitor for increased erythromycin and cobicistat effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib.  Management: Avoid this combination when possible. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose from 60 mg to 20 mg daily. Avoid concomitant use in patients already receiving reduced cobimetinib doses.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Avoidance, dose reduction, or increased monitoring for colchicine toxicity may be needed and will depend on brand, indication for colchicine use, renal/hepatic function, and use of a P-gp inhibitor. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Conivaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Conivaptan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Crizotinib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Crizotinib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Erythromycin (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Erythromycin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Erythromycin (Systemic). Management: Consider alternatives to this combination when possible. If combined, monitor for increased erythromycin effects and toxicities, including QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Dabrafenib.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and dabrafenib adverse effects when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.  Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Daridorexant.  Management: Limit the daridorexant dose to 25 mg, no more than once per night, when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Darifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOCEtaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Domperidone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxercalciferol: Erythromycin (Systemic) may increase the serum concentration of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Erythromycin (Systemic) may increase the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: May enhance the QTc-prolonging effect of Erythromycin (Systemic). Erythromycin (Systemic) may increase the serum concentration of Dronedarone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Erythromycin (Systemic) may increase the serum concentration of Edoxaban.  Management: In patients treated for DVT/PE, reduce the edoxaban dose to 30 mg daily when combined with erythromycin. No dose adjustment is recommended for patients treated for atrial fibrillation. Monitor for increased edoxaban toxicities (ie, bleeding) when combined<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elbasvir and Grazoprevir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.  Management: When combined with moderate CYP3A4 inhibitors, elexacaftor/tezacaftor/ivacaftor should be given in the morning, every other day. Ivacaftor alone should be given in the morning, every other day on alternate days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce eliglustat dose to 84 mg daily in CYP2D6 EMs when used with moderate CYP3A4 inhibitors. Avoid use of moderate CYP3A4 inhibitors in CYP2D6 IMs or PMs. Use in CYP2D6 EMs or IMs also taking strong or moderate CYP2D6 inhibitors is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Encorafenib. Management: Avoid use of encorafenib and moderate CYP3A4 inhibitors when possible. If combined, decrease encorafenib dose from 450 mg to 225 mg; 300 mg to 150 mg; and 225 mg or 150 mg to 75 mg. Monitor closely for QT interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Entrectinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: If coadministered with moderate CYP3A4 inhibitors, the max dose of eplerenone is 25 mg daily if used for heart failure; if used for hypertension initiate eplerenone 25 mg daily, titrate to max 25 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Erythromycin (Systemic) may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eszopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Everolimus.  Management: Afinitor: For TSC-associated SEGA or TSC-associated seizures reduce everolimus dose 50%. For other Afinitor indications, reduce everolimus dose to 2.5 mg/day, increase to 5 mg/day if tolerated. Zortress: Monitor for increased everolimus concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fedratinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Consider fentanyl dose reductions when combined with a moderate CYP3A4 inhibitor. Monitor for respiratory depression and sedation. Upon discontinuation of a CYP3A4 inhibitor, consider a fentanyl dose increase; monitor for signs and symptoms of withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Fexinidazole. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may decrease serum concentrations of the active metabolite(s) of Fexinidazole.  Management: Consider alternatives to this combination. If combined, monitor for QT interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QT prolongation may be at even higher risk. Also monitor for reduced fexinidazole efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin.  Management: Use of flibanserin with moderate CYP3A4 inhibitors is contraindicated. If starting flibanserin, start 2 weeks after the last dose of the CYP3A4 inhibitor. If starting a CYP3A4 inhibitor, start 2 days after the last dose of flibanserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May enhance the QTc-prolonging effect of Erythromycin (Systemic). Fluconazole may increase the serum concentration of Erythromycin (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Nasal): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosamprenavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosaprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Futibatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gepirone.  Management: Reduce the gepirone dose by 50% if combined with moderate CYP3A4 inhibitors. Monitor for QTc interval prolongation with combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Glasdegib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE.  Management: Reduce the extended-release guanfacine dose 50% when combined with a moderate CYP3A4 inhibitor. Monitor for increased guanfacine toxicities when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, decrease ibrutinib to 280 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Iloperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, the serum concentration of SN-38 may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Irinotecan Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Moderate) may increase isavuconazole serum concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions may be required; consult full drug interaction monograph content for age- and weight-specific dosage recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Ivosidenib. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: May enhance the QTc-prolonging effect of QT-prolonging CYP3A4 Substrates. Management: Do not use lefamulin tablets with QT-prolonging CYP3A4 substrates. Lefamulin prescribing information lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Leniolisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging CYP3A4 Substrates may enhance the QTc-prolonging effect of Levoketoconazole. Levoketoconazole may increase the serum concentration of QT-prolonging CYP3A4 Substrates. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomilnacipran: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomilnacipran. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Lidocaine (Systemic). Specifically, concentrations of monoethylglycinexylidide (MEGX) may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lincomycin: Erythromycin (Systemic) may diminish the therapeutic effect of Lincomycin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: Erythromycin (Systemic) may increase the serum concentration of Lovastatin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of Erythromycin (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lumateperone.  Management: Limit the lumateperone dose to 21 mg once daily when used with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: US labeling recommends reducing lurasidone dose by 50% with a moderate CYP3A4 inhibitor and initiating 20 mg/day, max 80 mg/day. Some non-US labels recommend initiating lurasidone 20 mg/day, max 40 mg/day. Avoid concurrent use of grapefruit products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurbinectedin.  Management: Avoid concomitant use of lurbinectedin and moderate CYP3A4 inhibitors when possible. If combined, consider a lurbinectedin dose reduction as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Maraviroc. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mavacamten.  Management: Start mavacamten at 5 mg/day if stable on a moderate CYP3A4 inhibitor. For those stable on mavacamten who are initiating a moderate CYP3A4 inhibitor, reduce mavacamten dose by one dose level.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Erythromycin (Systemic) may enhance the arrhythmogenic effect of Mequitazine.  Management: Concurrent administration of intravenous erythromycin with mequitazine is contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for increased methadone toxicities (eg, respiratory depression, QTc interval prolongation). Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methysergide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Methysergide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Midazolam.  Management: Avoid concomitant use of nasal midazolam and moderate CYP3A4 inhibitors. Consider alternatives to use with oral midazolam whenever possible and consider using lower midazolam doses. Monitor patients for sedation and respiratory depression if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mitapivat.  Management: When coadministered with moderate CYP3A4 inhibitors, doses of mitapivat should not exceed 20 mg twice daily. Additionally, patients should be monitored for changes in hemoglobin response and increased mitapivat adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mizolastine: Macrolide Antibiotics may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Mobocertinib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase serum concentrations of the active metabolite(s) of Mobocertinib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Mobocertinib.  Management: Avoid use of QT prolonging moderate CYP3A4 inhibitors with mobocertinib when possible. If combined, the mobocertinib dose should be reduced by approximately 50% (ie, from 160 mg to 80 mg, 120 mg to 40 mg, or 80 mg to 40 mg). Monitor QTc interval closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol.  Management: The use of naloxegol and moderate CYP3A4 inhibitors should be avoided. If concurrent use is unavoidable, reduce naloxegol dose to 12.5 mg once daily and monitor for signs of opiate withdrawal (eg, hyperhidrosis, chills, diarrhea, anxiety, irritability).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Nintedanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib.  Management: Avoid use of moderate CYP3A4 inhibitors with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib tablets should be reduced to 150 mg twice daily and the dose of olaparib capsules should be reduced to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Omaveloxolone.  Management: Avoid this combination if possible. If coadministration is required, decrease the omaveloxolone dose to 100 mg daily and monitor closely for adverse reactions. If adverse reactions occur, decrease omaveloxolone to 50 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyBUTYnin: Erythromycin (Systemic) may increase the serum concentration of OxyBUTYnin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palovarotene.  Management: Avoid concomitant use of palovarotene and moderate CYP3A4 inhibitors when possible. If combined, decrease palovarotene dose by 50% as described in the full interaction monograph. Monitor for palovarotene toxicities when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Panobinostat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Erythromycin (Systemic) may enhance the QTc-prolonging effect of PAZOPanib. Erythromycin (Systemic) may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pemigatinib.  Management: If combined use cannot be avoided, reduce the pemigatinib dose from 13.5 mg daily to 9 mg daily, or from 9 mg daily to 4.5 mg daily. Resume prior pemigatinib dose after stopping the moderate inhibitor once 3 half-lives of the inhibitor has passed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pexidartinib.  Management: If combined use cannot be avoided, pexidartinib dose should be reduced. For the 125 mg capsules: reduce pexidartinib doses of 500 mg or 375 mg daily to 125 mg twice daily. Reduce pexidartinib 250 mg daily to 125 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimavanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pirtobrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitavastatin: Erythromycin (Systemic) may increase the serum concentration of Pitavastatin.  Management: Limit pitavastatin to a maximum of 1 mg/day when used in combination with erythromycin. If this combination is used, monitor patients more closely for evidence of pitavastatin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pivmecillinam: Erythromycin (Systemic) may diminish the therapeutic effect of Pivmecillinam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pravastatin: Erythromycin (Systemic) may increase the serum concentration of Pravastatin.  Management: Limit pravastatin dose to a maximum of 40 mg/day when used in combination with erythromycin. If this combination is used, monitor patients more closely for evidence of pravastatin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazepam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Prazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of Erythromycin (Systemic). Erythromycin (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk). Erythromycin (Systemic) may increase the serum concentration of QT-prolonging Class IA Antiarrhythmics (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class III Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of Erythromycin (Systemic). Erythromycin (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk). Management: Avoid concomitant use of erythromycin and class III antiarrhythmic agents. Use of erythromycin with dronedarone is specifically contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Kinase Inhibitors (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Kinase Inhibitors (Moderate Risk). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Highest Risk): QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Miscellaneous Agents (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): Erythromycin (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Erythromycin (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of Erythromycin (Systemic). QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of Erythromycin (Systemic). Management: Consider alternatives to this combination. If combined, monitor for increased erythromycin toxicities, including QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): Erythromycin (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Erythromycin (Systemic).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QUEtiapine. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QUEtiapine.  Management: Monitor for increased quetiapine toxicities including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: Erythromycin (Systemic) may enhance the QTc-prolonging effect of QuiNIDine. Erythromycin (Systemic) may increase the serum concentration of QuiNIDine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Quinidine (Non-Therapeutic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors. Monitor for increased ranolazine effects and toxicities during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: Erythromycin (Systemic) may increase the serum concentration of Red Yeast Rice. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: Erythromycin (Systemic) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rifabutin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Macrolide Antibiotics may increase the serum concentration of Rilpivirine.  Management: Consider the use of azithromycin or another non-macrolide alternative when appropriate to avoid this potential interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rimegepant.  Management: If taking rimegepant for the acute treatment of migraine, avoid a second dose of rimegepant within 48 hours when used concomitantly with moderate CYP3A4 inhibitors. No dose adjustment needed if using rimegepant for prevention of episodic migraine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rimegepant.  Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: May enhance the QTc-prolonging effect of Erythromycin (Systemic). Erythromycin (Systemic) may increase the serum concentration of RisperiDONE. Management: Monitor for increased risperidone toxicities, including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Rivaroxaban.  Management: No action is needed in patients with normal renal function. Do not use this combination in patients with estimated creatinine clearance 15 to 80 mL/min unless prospective benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ruxolitinib (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Erythromycin (Systemic) may enhance the QTc-prolonging effect of Saquinavir. Erythromycin (Systemic) may increase the serum concentration of Saquinavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Selpercatinib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Selpercatinib.  Management: Avoid combination if possible. If use is necessary, reduce selpercatinib dose as follows: from 120mg twice/day to 80mg twice/day, or from 160mg twice/day to 120mg twice/day. Monitor QT interval more closely for QTc interval prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selumetinib.  Management: Avoid concomitant use when possible. If combined, selumetinib dose reductions are recommended and vary based on body surface area and selumetinib dose. For details, see the full drug interaction monograph or selumetinib prescribing information.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Sertindole. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Sertindole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: Erythromycin (Systemic) may enhance the adverse/toxic effect of Sertraline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: Erythromycin (Systemic) may increase the serum concentration of Sildenafil.  Management: For pulmonary arterial hypertension, no dose adjustment required. For erectile dysfunction, consider using a lower starting dose of 25 mg in patients who are also taking erythromycin. Monitor patients for sildenafil toxicities when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: Erythromycin (Systemic) may increase the serum concentration of Simeprevir. Simeprevir may increase the serum concentration of Erythromycin (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: Erythromycin (Systemic) may increase serum concentrations of the active metabolite(s) of Simvastatin. Erythromycin (Systemic) may increase the serum concentration of Simvastatin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): Erythromycin (Systemic) may increase the serum concentration of Sirolimus (Conventional). Sirolimus (Conventional) may increase the serum concentration of Erythromycin (Systemic).  Management: Monitor for increased serum concentrations of sirolimus if combined with erythromycin. Lower initial sirolimus doses or sirolimus dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Solifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib.  Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible.  When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sparsentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of SUNItinib. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of SUNItinib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant.  Management: The recommended dose of suvorexant is 5 mg daily in patients receiving a moderate CYP3A4 inhibitor. The dose can be increased to 10 mg daily (maximum dose) if necessary for efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Erythromycin (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tazemetostat.  Management: Avoid when possible. If combined, reduce tazemetostat dose from 800 mg twice daily to 400 mg twice daily, from 600 mg twice daily to 400 mg in AM and 200 mg in PM, or from 400 mg twice daily to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terfenadine: May enhance the QTc-prolonging effect of Erythromycin (Systemic). Erythromycin (Systemic) may enhance the QTc-prolonging effect of Terfenadine. Erythromycin (Systemic) may increase the serum concentration of Terfenadine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor and Ivacaftor.  Management: If combined with moderate CYP3A4 inhibitors, give tezacaftor/ivacaftor in the morning, every other day; give ivacaftor in the morning, every other day on alternate days. Tezacaftor/ivacaftor dose depends on age and weight; see full Lexi-Interact monograph<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Erythromycin (Systemic) may increase the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of Erythromycin (Systemic).  Management: Consider alternatives to this combination. If combined, monitor for increased serum concentrations/toxic effects of theophylline derivatives.Theophylline derivative dose reductions may be needed. Also monitor for reduced erythromycin efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tofacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolterodine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.  Management: Avoid this combination with Samsca brand of tolvaptan. Reduce dose for Jynarque brand: 90 mg AM and 30 mg PM, reduce to 45 mg AM and 15 mg PM; 60 mg AM and 30 mg PM, reduce to 30 mg AM and 15 mg PM; 45 mg AM and 15 mg PM, reduce to 15 mg AM and PM.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of TraMADol. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Triazolam.  Management: Consider triazolam dose reduction in patients receiving concomitant moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and avoid a second dose for 24 hours when used with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vamorolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vamorolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vardenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vardenafil.  Management: Limit Levitra (vardenafil) dose to a single 5 mg dose within a 24-hour period if combined with moderate CYP3A4 inhibitors. Avoid concomitant use of Staxyn (vardenafil) and moderate CYP3A4 inhibitors. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with moderate CYP3A4 inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinBLAStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinBLAStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinCRIStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Vinflunine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vinflunine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Voclosporin.  Management: Decrease the voclosporin dose to 15.8 mg in the morning and 7.9 mg in the evening when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vorapaxar. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zafirlukast: Erythromycin (Systemic) may decrease the serum concentration of Zafirlukast. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zanubrutinib.  Management: Decrease the zanubrutinib dose to 80 mg twice daily during coadministration with a moderate CYP3A4 inhibitor. Further dose adjustments may be required for zanubrutinib toxicities, refer to prescribing information for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuranolone. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F8086293"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Food: Erythromycin serum levels may be altered if taken with food (formulation-dependent). GI upset, including diarrhea, is common. Management: May be taken with food to decrease GI upset, otherwise take around-the-clock with a full glass of water. Do not give with milk or acidic beverages (eg, soda, juice).</p></div>
<div class="block pri drugH1Div" id="F8086264"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Erythromycin crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Cardiovascular anomalies following exposure in early pregnancy have been reported in some observational studies.</p>
<p style="text-indent:0em;margin-top:2em;">Serum concentrations of erythromycin may be variable in pregnant patients (Kiefer 1955; Philipson 1976).</p>
<p style="text-indent:0em;margin-top:2em;">Erythromycin is the antibiotic of choice for preterm prelabor rupture of membranes &lt;34 0/7 weeks' gestation) (ACOG 188 2018), the treatment of lymphogranuloma venereum in pregnancy, and the treatment of or long-term suppression of <i>Bartonella </i>infection in HIV-infected pregnant patients. Erythromycin is one of the antibiotics that may be used for the treatment of chancroid or granuloma inguinale during pregnancy (consult current guidelines) (CDC [Workowski 2021]; HHS [OI adult] 2022). Agents other than systemic erythromycin are preferred for the treatment of acne during pregnancy (AAD [Zaenglein 2016]).</p></div>
<div class="block brc drugH1Div" id="F8086272"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Loss of appetite, diarrhea, rash, and somnolence have been reported in breastfeeding infants exposed to macrolide antibiotics (Goldstein 2009). Irritability and orange-red stool discoloration have also been reported following erythromycin exposure (Ito 1993; Stang 1986). In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush, dehydration, or diarrhea (Butler 2014; WHO 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">One case report and a cohort study raise the possibility for a connection with pyloric stenosis in neonates exposed to erythromycin via breast milk; an alternative antibiotic may be preferred for breastfeeding mothers of infants in this age group (Sørensen 2003; Stang 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">Although the manufacturer recommends caution be used if administered to a breastfeeding patient, erythromycin is considered compatible when used in usual recommended doses (WHO 2002). Erythromycin is a preferred agent for the treatment of granuloma inguinale and lymphogranuloma venereum in breastfeeding patients (CDC [Workowski 2021]). If systemic erythromycin is needed for the treatment of dermatologic conditions, only short-term use is recommended if breastfeeding (Butler 2014).</p></div>
<div class="block dic drugH1Div" id="F8086410"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p>
<p style="text-indent:-2em;margin-left:2em;">Base, PCE or stearate dosage forms should be taken on an empty stomach (2 hours before or after a meal).</p>
<p style="text-indent:-2em;margin-left:2em;">Ethylsuccinate (EES) or delayed-release (ERY-TAB) dosage forms may be administered without regards to meals. </p>
<p style="text-indent:-2em;margin-left:2em;">May consider administering after food to decrease GI discomfort.  </p></div>
<div class="block mop drugH1Div" id="F57520295"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Changes in frequency of bowel movements. Liver and renal function (with prolonged use). Blood pressure and heart rate (with IV use or as clinically appropriate). Signs of hypertrophic pyloric stenosis (eg, feeding intolerance, emesis) in neonates and young infants.</p></div>
<div class="block pha drugH1Div" id="F8086369"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Antibiotic: Inhibits RNA-dependent protein synthesis at the chain elongation step; binds to the 50S ribosomal subunit resulting in blockage of transpeptidation.</p>
<p style="text-indent:-2em;margin-left:2em;">Gastric motility: Agonizes motilin receptors, possibly regulating phase III of the migrating motor complex (MMC), resulting in antral and duodenal peristalsis (Curry 2001; Febo-Rodriguez 2019; Tillman 2016).</p></div>
<div class="block phk drugH1Div" id="F8086371"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Variable but better with salt forms than with base form; 18% to 45%; ethylsuccinate may be better absorbed with food (Coyne 1978; Eriksson 1981; Thompson 1980).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm neonates (GA: 23 to 29 weeks; PNA: 2 to 15 days): Lactobionate (IV): Mean range: 1.9 to 2.4 L/kg (Waites 1994).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.64 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Relative diffusion from blood into CSF: Minimal even with inflammation.</p>
<p style="text-indent:-2em;margin-left:4em;">CSF:blood level ratio: Normal meninges: 2% to 13%; Inflamed meninges: 7% to 25%.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Base: 73% to 81%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Demethylation primarily via hepatic CYP3A4.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates (GA: 23 to 29 weeks; PNA: 2 to 15 days): Lactobionate (IV): Mean range: 1.9 to 2.1 hours (Waites 1994).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and Infants &lt;4 months: Ethylsuccinate (oral): 2.42 ± 0.31 hours (Patamasucon 1981).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months and Children &lt;4 years: Ethylsuccinate (oral): Mean range: 1.4 to 1.7 hours (McCracken 1978).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Peak: 1.5 to 2 hours; End-stage renal disease: 5 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: <b>Note:</b> Delayed with food due to differences in absorption.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and Infants &lt;4 months: Ethylsuccinate (oral): Initial dose: 1.8 ± 0.48 hours; Steady state: 0.8 ± 0.11 hours (Patamasucon 1981).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children ≤5 years: Ethylsuccinate (oral): 0.5 to 1.5 hours (Coyne 1978).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Base: 4 hours; Ethylsuccinate: 0.5 to 2.5 hours; Stearate: 3 hours (Steigbigel 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily feces; urine (2% to 15% as unchanged drug).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10962015"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dumotrycin | E mycin | Eritrolag | Eromycin | Ery | Erylan | Erythrocin | Erythrodar | Erythromil | Iloson | Mephamycine | Omathrocin | Servitrocin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ambamida | Erigrand | Erigrand forte | Erit bioquim | Eritromicina | Eritromicina fabra | Eritromicina Hlb | Eritromicina klonal | Eritromicina lafedar | Etisux | Ilosone | Pantomicina | Wemid</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Erystad | Erythrocin | Erythromycin genericon pharma | Meromycin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dbl erythromycin | E-mycin | Ees | Eryc | Eryhexal | Erythrocin | Erythromycin Base | Erythromycin link | Erythromycin panpharma | Erythromycin sxp | Ilosone</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">A mycin | Acryth | E-Bac | Ecin | Eltocin | Emycin | Eres | Erixin | Ermac | Erocin | Erom | Eromac | Eromed | Eromycin | Erona | Erosa | Erosil | Erosite | Errin | Ery | Erycin | Erylin | Erymex | Erynet | Eryped | Eryrox | Erythin | Erythrox | Ethro | Etrocin | Euro | Firmac | Ilocin | Kumucin | Mac | Macas | Macin | Macrocin | Makcin | Priocin | Rhythm | Servitrocin | Stocin | Throcin | Zerobac | Zuracin | Zuracyn</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Erythro-250 | Erythrocine | Erythroforte | Erythromycine mayne pharma (ben)</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Cary | Ery | Erythromycine | Rycin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Erythran</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Eribiotic | Ericloran | Eriflogin | Erimicina | Eripan | Eritax | Eritrex | Eritrin | Eritroben | Eritrofar | Eritromed | Eritromicina | Eritrovit | Eritroxin | Estolato de eritromicina | Ilosone | Inflax | Kanazima | Neo eritromicin | Pantomicina | Rubromicin | Siftrex | Tromaxil | Valmicin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cimetrin | Cimetrin Stearat | Dumotrycin | Erythrocin | Erytran | Ilosone | Monomycin | Servitrocin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Apo-erythro | Cary | Erilide</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Eritromicina | Erypark | Mercina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ao shu xin | Bi bang | Bo li sha | Bo ya | Davercin | Eryc | Erythromycin | Erythromycin es | Erythromycin ethyl | Erythromycin lactate | Ha sen li sha | Ka luo | Kang yan qing | Lai te xin | Li jun sha | Sai neng shu | Wh-etimycine | Xi li kang | Xin gong kang | Yi da bi xin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Eritromicina | Eritromicina estearato | Eritromicina etilsuccinato | Eritromicina mk | Ilosone | Mopen | Pantomicina | Pantomicina es | Pantopenil | Pantoplus | Pce | Seritromicina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Emu V | Erasis | Eryc | Erythrocin | Meromycin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ab erythromycin | Dura erythromycin | Durapaediat | Ery | Ery diolan | Ery reu | Erybeta | Erycinum | Eryhexal | Erysec | Erythro hefa | Erythrocin | Erythromycin | Erythromycin Actavis | Erythromycin al | Erythromycin Delta Select | Erythromycin inresa | Erythromycin panpharma | Erythromycin rotex | Erythromycin stragen | Erytromycin Stearate 1 A Pharma | Karex | Paediathrocin | Sanasepton</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ees | Eritrex | Eritromer | Eritromicina | Eritromicina estearato | Eritromicina estolato | Eritromicina medek | Erixil | Eromicina | Eutimol | Monomycina | Pamicil | Pantomicina | Ritrolac</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Baknyl | Eriecu | Eritrocin T | Eritromicina | Eritromicina ariston | Eritromicina etilnilsuccinato | Eritromicina etinilsuccinato | Eritromicina mk | Eritromicina NIFA | It-erichem | Libramicina | Monomycina | Pantomicina | Servitrocin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Abboticin | Emu V | Erasis | Eritromicina normon | Erybesan | Erycyclin | Erythran | Erythrocin | Erythrocin lactobionate | Erythromycin inresa | Erythromycin ns | Erythromycin ratiopharm | Erythromycin stragen | Erythromycin Teva | Erythromycin-dyna | Ilosone | Porfyrocin | Porphyrocin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Eryped | Erythrin | Erythrocin | Erythromycin | Erythroriv | Razimycin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bronsema | Doranol | Eritrogobens | Eritromicina estedi | Eritroveinte | Ery-max | Lagarmicin | Neo iloticina | Pantomicina</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Erycin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Abboticin | Abboticin novum | Erasis | Ermysin | Ermysin s | Eromyna | Ilosone | Ilotycin gluceptat</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Abboticine | Egery | Emestid | Ery | Eryphar | Erythrocine | Erythromycine dakota | Erythromycine merck | Erythromycine panpharma | Logecine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Arpimycin | Ermysin | Erycen | Erymin | Erythoden | Erythrocin | Erythrocin I.V. Lactobionate | Erythrolar | Erythromycin | Erythromycin almus | Erythromycin arrow | Erythromycin berk | Erythromycin cox | Erythromycin dc | Erythromycin focus | Erythromycin kent | Erythromycin Teva | Erythroped | Erythroped a | Ilosone | Kerymax | Retcin | Rommix | Tiloryth</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Emgimycin | Enamycin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Erythrocin | Erythropen | Puntol | Roug mycin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">APO ERYTHRO BASE | Apo-erythro | Apo-Erythro EC | Codacin | Ees | Elosone | Ericin | Erismycine | Erogran | Erotab | Eryc | Erymycin | Erythro ethyl | Erythrobase | Erythrocin | Erythrocin stearat | Erythrolate | Erythromycin | Ilosone | Isomycin | Neo-Throcin | Nice erycin | Oracin | Pce | Porphyrocin | Rycin | U esone</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Eritromicin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Eryc | Erythran | Erythromycin panpharma | Erythrotrop | Meromycin | Servitrocin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Althrocin | Arsitrocin | Bannthrocin | Camitrocine | Cetathrocin | Corsatrocin | Decathrocin | Dexythrocin | Dothrocyn | Duramycin | E-Mycin | Ebalin | Ees | Enkathrocyn | Erisina | Eritromec | Eros | Erphatrocin | Erybiotic | Erycoat | Erysanbe | Erythrin | Erythrocin | Erythromycin | Erythromycin ethyl succinate | Ikathrocin | Kalthrocin | Kenthrocin | Konithrocin | Narlecin | Opithrocin | Pharothrocin | Primacine | Primathrocin | Rythron | Scantrocin | Throcidan | Tromilin | Trovilon | Xepatrocin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Erythrocin | Erythromycin | Erythroped | Primacine | Tiprocin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Erythro-teva</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alithro | Althrocin | Arithro | Calthrox | Citamycin | E-Mycin | Ees | Eltocin | Eltocin ds | Elucin | Emthrocin | Erase | Eroate | Eromed | Eromyn | Erotech | Ery | Eryc-s | Erycin | Erypal | Erysafe | Erysoft | Eryster | Erytas | Erythrocin | Erythrolar | Erythromark | Erythromycin | Erythronij | Erythrosain | Erythrotone | Erywok | Etomin | Galthrox | Gethro | Inderyth | Macrocin | Micromycin | Nithro | Okamycin | Ranthrocin | Rekcin | Restomycin | Rethrocin | Rithromed | Thromycin | Urticom</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Awamycin | Ritrom</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Eritrocina | Ilosone | Lauromicina | Zalig</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Eryped | Erythrocent | Erythrocin | Erythrodar | Erythromil | Propiocin | Rythromac</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Abomacetin | Erythro S | Erythro st | Erythro yamakawa | Erythrocin | Erythromycin | Erythromycin abbott | Erythromycin amel | Erythromycin fujimoto | Erythromycin galen | Erythromycin iwaki | Erythromycin kaken | Erythromycin kissei | Erythromycin merck | Erythromycin organon | Erythromycin otsuka | Erythromycin pharm | Erythromycin sawai | Erythromycin st.towa | Erythromycin taisho | Erythromycin teikoku | Erythromycin teisan | Erythromycin tobishi | Ilosone | Ilotycin | Taimoxin | Takasunon</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Arycin | Asomycin | Biotrocin | Elocin | Erilide | Ero | Erocin | Erocin paediatric | Erocos | Erocos st | Eromycin | Eromycin pfs | Eryc-s | Erycin | Erygyl | Erythro | Erythrokant | Erythrolite | Erythromed | Erythromin | Erythromycin | Erythrox | Erythyl | Ethro | Etocin | Indo | Labcin | Throcin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Derimer | Ebrosin | Eromycin | Eropacin | Erymicin | Erypion | Erysys | Erytab | Erythro | Erythro p | Erythrocin | Erythromycin | Estholin | Grendacine | Ilosone | Stinosec</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo-Erythro e-c | Eromycin | Erythrocin | Erythrodar | Omathrocin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Emu V | Ery | Erythrine | Erythrocin | Medithrocin | Propiocine | Rycin | Stellamicina</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">E mycin | Emu V | Erybesan | Eryc | Erycyclin | Eryped | Erythran | Erythrocin | Erythromycin panpharma | Erytran | Laurylin | Monomycin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ery | Eryhexal | Erythrocine | Erythroforte</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Emu V | Eritromicina fisiopharma | Eryc | Erycyclin | Eryhexal | Eryped | Erythrocin | Erythromycin panpharma | Erythromycin Rph | Erytran | Ilosone | Indo | Laurylin | Mephamycine | Monomycin | Porphyrocin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Abboticine | Ery | Erythrocin | Marocid | Propiocine | Rybac</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Benitrom | Biotril | Colitromin | E-trocima-p | Eribec | Eriber | Eritrolat | Eritromicina | Eritromicina g.i.k | Eritromicina gi se | Eritroquim | Eritrovier | Eritrovier s | Eritrovier t | Eritrowel | Erylar | Erylar st | Eurocin | Gentromicina | Ilosin | Ilosone | Iqfamicina | Iretron | Latotryd | Lauricin | Laurimicina | Lauritran | Pantomicina es | Quilamicina | Trimocina | Tropharma | Witromin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Axcel-Erythromycin | Dyna Erythromycin | E.E.S. | Ees | Elthrocin | Eomycin | Ericin | Erotab | Erycin | Erymin 400 | Erymycin | Eryped | Eryson | Erytab-S | Erythro | Erythro ethyl | Erythrocin | Erythromycin | Erythromycin pharmaniaga | Etrogran | Ettrocin | Pharmaniaga Erythromycin | Ranthrocin | Retorin | Sathrocin | Sathrocin ES | Sathrocin S | Sethro</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Acithromac | Amakin erythromycin | Benow erythromycin | Chardnett erythromycin | Chazmax erythromycin | Donitrocin | Drug zone erythromycin | Elatrocin | Emek jiors erythromycin stearate | Erlicin | Eroceth | Eryfast | Erygloba | Erysuit | Erythrofaith | Erythromycin | Etocin | Eythr | Festmycin | G throcine | Grams erythromycin | Harvad | Hochitrocin | Johnbee erythromycin | Kayhelt erythromycin | Kezz erythromycin | Koyocin | Krishat erythromycin stearate | Kristhromycin | Me cure's erythromycin | Mexzen erythromycin | Nelb erythromycin | Nemel erythro | Osyricin | Rycin | Sunymet erythromycin | Tamar &amp; pharez erythromycin | Throtal | Topix erythromycin | Vadimycin | Vineryth | Zest erythromycin | Zymethrocin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Eryc | Eryderm | Erythrocine | Erythrocine es | Erythromycine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Abboticin | Abboticin es | Ery-max | Erythroforte | Erythromycin panpharma | Erythroped a | Primacine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">E-mycin | Ees | Era | Eromycin | Eryc | Erythrocin</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Omathrocin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Apo-erithro-s | Broncomicin | Broncotromicina | Erilan | Eriquilab | Eritrears | Eritromac | Eritromicina | Eritromicina estearato | Eritromin | Erylan | Erytro | Erytrom | Esterit | Ilocin | Ilosone | Pantomicina | Selvicin | Servitrocin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Almycin | Ecolide | Epertocyn | Erycar | Erycin | Erylide | Erymax | Erysaph t | Erysone | Erythrocin | Erythrolan | Erythromycin | Erythromycin ethyl succinate | Ethiocin | Etriogape | Fildrocin | Ilosone | Jethrocin | Macrocin | Monphevin | Pertustat | Sefavex | Servitrocin | Tgp erythro | Tromxene</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Acumen | D-mycin | Emycin | Erithrin | Erycina | Erysin | Erytab | Erythro | Erythrocin | Erythromycin | Erythrotab | Erythrovel | Erywil | Geoerythcin | Irzacin | Novomycin | Ocemycin | Tiloryth | Trocin | Trycin | Wilmycin | Wotez</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Davercin | Erythrocin | Erythromycinum | Laurylin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">E-Mycin | Ees | Ery-Tab | Eryc | Erythrocin Lactate | Erythrocin Stearate | Erythromycin | Erythromycin Base | Erythromycin lactate | Ilosone</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">E.s.e. | Eritina | Eritrocel | Eritrocina | Eritrocina forte | Eritromicina | Eritromicina normon | Eryc</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Erigran | Eritric | Eritroland | Eritromicina dutriec | Eritromicina p.a.n. | Manilin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Eromycin | Eromycin Granules | Erythrocin IV | Erythrodar | Omathrocin | Omathrocin Drops | Omathrocin Stearate</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Eritro | Eritromagis | Eritromicina | Eritromicina Atb | Eritromicina Sandoz | Eryc | Erythrodar</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Eomycin | Eryc | Erycyclin | Erythromycin | Erytran | Sineryt</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Eromycin | Eryped | Erythrocin | Erythrodar | Erythromil | Erythromycin panpharma | Omathrocin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Abboticin | Abboticin novum | Ery max | Ery-max | Erythromycin ebb | Erythromycin panpharma | Erytromycin | Polarmycina</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">E.E.S. | Ees | Ermycin | Erogran | Erotab | Eryc | Erycyn | Eryped | Eryson | Erytab-S | Erythro | Erythro ethyl | Erythrocin | Erythromycin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Eritromicin | Erycinum | Erythrocine | Erythromycin | Erythromycin inresa | Pantomicina</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Porphyrocin</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Erymik</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Codacin | E throcin | Ecs | Elocin | Erathrom | Ericin | Erimit | Erimycin | Erithmycin | Erolex | Ery-Tab | Erycin | Erycon | Erymed | Erymin | Eryo | Erysate | Erysil | Erysol | Erytacin | Erythro | Erythrocin | Erythromed | Erythromin | Erythromycin | Erythron | Erytomin | Erytrex | Estab | Estocin | Ethocin | Ethromed | Etrolate | Ilosone | Irosa | Latocin s | Malocin | Manilin | Medthrocin | Moryto | Newtrocin | Pharthrocin | Pocin | Porphyrocin | Ranthrocin | Redrocin | Retocin | Rintacap | Rintacin | Rithrocin | Rytho | Rythocin | Rytrocin | Servitrocin | Stacin | Starthrocin | Suthrocin | Ticomycin | Tomcin | Trocin | Verythro</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Abboticine | Ery | Erythro | Erythrocine | Erythrodar | Erythromil | Propiocine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Erimicin | Eritro | Eritrosif | Erythrocin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bristamycin | Delason s | Erocin | Eromycin | Ery-b | Eryc | Erycin | Erycine | Eryhexal | Erymycin | Erymycin-l | Eryson | Erysone | Erysrocin | Erystac | Erythrocin | Erythrocin lactobionate | Erythromycin | Erythromycin Base | Erytrarco | Esmycin | Ethromycin s | Hylomycin | Illomycin | Ilomycin | Ilosone | Irose | Kerymycin | Nyslosone | Ritesone | S.k.j. | Servitrocin | Sunthrocin | Ulosina | Uloson | Walosone | Yuenmycin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Althrocin s | Azinom | Erycyclin | Erythrolet</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Asomycin | Elocin | Ero | Erymycin | Erythrokant | Erythrone | Erythroren | Erythyl | Kam erymycin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Eritromicina | Farmicina | Pantomicina | Pantomicina Ees | Servitrocin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Eritrex | Eritromicina | Eritroped | Ilosone | Laurimicina | Pantomicina | Yisadin</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agi ery</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">A L Erythromycin | Adco-erythromycin | Betamycin | Emysn | Eromel | Eryko | Erymax | Erymin | Erymycin | Erythrocin | Erythroped | Estomycin | Ethimycin | Ilosone | Merck-erythromycin | Micro-erythromycin | Purmycin | Racemin | Rubimycin | Spectrasone | Succilate | Succin | Xeramel</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Apthromycin | Elocin | Eromycin | Erotab | Erycach | Erycin | Eryko | Erymin | Erythro | Erythrokant | Erythromycin | Indo</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Eromel | Eryest | Etrocin | Indo | Rythrocaps</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30470884">
<a name="30470884"></a>Abdellatif M, Ghozy S, Kamel MG, et al. Association between exposure to macrolides and the development of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis. <i>Eur J Pediatr</i>. 2019;178(3):301-314. doi:10.1007/s00431-018-3287-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/30470884/pubmed" id="30470884" target="_blank">30470884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Abramowicz.1">
<a name="Abramowicz.1"></a>Abramowicz M. Antimicrobial Prophylaxis in Surgery. <i>Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy</i>. 16th ed. New York, NY: Medical Letter; 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21145052">
<a name="21145052"></a>Altraif I, Handoo FA, Aljumah A, et al. Effect of erythromycin before endoscopy in patients presenting with variceal bleeding: a prospective, randomized, double-blind, placebo-controlled trial. <i>Gastrointest Endosc</i>. 2011;73(2):245-250. doi:10.1016/j.gie.2010.09.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/21145052/pubmed" id="21145052" target="_blank">21145052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17036029">
<a name="17036029"></a>Aly H, Abdel-Hady H, Khashaba M, El-Badry N. Erythromycin and feeding intolerance in premature infants: a randomized trial. <i>J Perinatol</i>. 2007;27(1):39-43. doi:10.1038/sj.jp.7211618<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/17036029/pubmed" id="17036029" target="_blank">17036029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29794679">
<a name="29794679"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 737: Expedited partner therapy. <i>Obstet Gynecol</i>. 2018;131(6):e190-e193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/29794679/pubmed" id="29794679" target="_blank">29794679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21606770">
<a name="21606770"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. <i>Obstet Gynecol</i>. 2011;117(6):1472-1483. Available at<a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank"> http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/21606770/pubmed" id="21606770" target="_blank">21606770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27661655">
<a name="27661655"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 172: Premature rupture of membranes. <i>Obstet Gynecol</i>. 2016;128(4):e165-e177. doi: 0.1097/AOG.0000000000001712<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/27661655/pubmed" id="27661655" target="_blank">27661655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15127872">
<a name="15127872"></a>American Dental Association Council on Scientific Affairs, "Combating Antibiotic Resistance," <i>J Am Dent Assoc</i>, 2004, 135(4):484-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/15127872/pubmed" id="15127872" target="_blank">15127872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, eds. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21615438">
<a name="21615438"></a>Bai Y, Guo JF, Li ZS. Meta-analysis: erythromycin before endoscopy for acute upper gastrointestinal bleeding. <i>Aliment Pharmacol Ther</i>. 2011;34(2):166-171. doi:10.1111/j.1365-2036.2011.04708.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/21615438/pubmed" id="21615438" target="_blank">21615438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20970794">
<a name="20970794"></a>Barkun AN, Bardou M, Martel M, Gralnek IM, Sung JJ. Prokinetics in acute upper GI bleeding: a meta-analysis. <i>Gastrointest Endosc</i>. 2010;72(6):1138-1145. doi:10.1016/j.gie.2010.08.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/20970794/pubmed" id="20970794" target="_blank">20970794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33044576">
<a name="33044576"></a>Basu S, Smith S. Macrolides for the prevention and treatment of feeding intolerance in preterm low birth weight infants: a systematic review and meta-analysis. <i>Eur J Pediatr</i>. 2021;180(2):353-378. doi:10.1007/s00431-020-03814-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/33044576/pubmed" id="33044576" target="_blank">33044576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1670695">
<a name="1670695"></a>Boyd I. Erythromycin-induced hearing loss. <i>Lancet</i>. 1991;337(8733):113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/1670695/pubmed" id="1670695" target="_blank">1670695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society (PIDS) and the Infectious Diseases Society of America (IDSA). <i>Clin Infect Dis.</i> 2011;53(7):e25-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. <i>Am J Health Syst Pharm.</i> 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Butler.1">
<a name="Butler.1"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.e1-10.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23147521">
<a name="23147521"></a>Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L; American College of Gastroenterology. Clinical guideline: management of gastroparesis. <i>Am J Gastroenterol</i>. 2013;108(1):18-37; quiz 38. doi:10.1038/ajg.2012.373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/23147521/pubmed" id="23147521" target="_blank">23147521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16771939">
<a name="16771939"></a>Carbonell N, Pauwels A, Serfaty L, Boelle PY, Becquemont L, Poupon R. Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. <i>Am J Gastroenterol</i>. 2006;101(6):1211-1215.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/16771939/pubmed" id="16771939" target="_blank">16771939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1568663">
<a name="1568663"></a>Catnach SM and Fairclough PD, “Erythromycin and the Gut,” <i>Gut</i>, 1992, 33(3):397-401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/1568663/pubmed" id="1568663" target="_blank">1568663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15755792">
<a name="15755792"></a>Chicella MF, Batres LA, Heesters MS, et al. Prokinetic drug therapy in children: A review of current options. <i>Ann Pharmacother</i>. 2005;39(4):706-711.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/15755792/pubmed" id="15755792" target="_blank">15755792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12145593">
<a name="12145593"></a>Coffin B, Pocard M, Panis Y, et al; Groupe des endoscopistes de garde á l'AP-HP. Erythromycin improves the quality of EGD in patients with acute upper GI bleeding: a randomized controlled study. <i>Gastrointest Endosc</i>. 2002;56(2):174-179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/12145593/pubmed" id="12145593" target="_blank">12145593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12090829">
<a name="12090829"></a>Cooper WO, Griffin MR, Arbogast P, Hickson GB, Gautam S, Ray WA. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. <i>Arch Pediatr Adolesc Med</i>. 2002;156(7):647-650. doi:10.1001/archpedi.156.7.647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/12090829/pubmed" id="12090829" target="_blank">12090829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11641030">
<a name="11641030"></a>Costalos C, Gavrili V, Skouteri V, Gounaris A. The effect of low-dose erythromycin on whole gastrointestinal transit time of preterm infants. <i>Early Hum Dev</i>. 2001;65(2):91-96. doi:10.1016/s0378-3782(01)00191-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/11641030/pubmed" id="11641030" target="_blank">11641030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-632366">
<a name="632366"></a>Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC. Bioavailability of erythromycin ethylsuccinate in pediatric patients. <i>J Clin Pharmacol</i>. 1978;18(4):194-202. doi:10.1002/j.1552-4604.1978.tb01593.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/632366/pubmed" id="632366" target="_blank">632366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1825670">
<a name="1825670"></a>Council on Dental Therapeutics; American Heart Association. Preventing bacterial endocarditis: a statement for the dental professional. Council on Dental Therapeutics; American Heart Association [published correction appears in <i>J Am Dent Assoc</i>. 1991;122(4):21.] <i>J Am Dent Assoc</i>. 1991;122(2):87-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/1825670/pubmed" id="1825670" target="_blank">1825670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11328252">
<a name="11328252"></a>Curry JI, Lander TD, Stringer MD. Review article: erythromycin as a prokinetic agent in infants and children. <i>Aliment Pharmacol Ther</i>. 2001;15(5):595-603. doi:10.1046/j.1365-2036.2001.00964.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/11328252/pubmed" id="11328252" target="_blank">11328252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2146414">
<a name="2146414"></a>Dajani AS, Bisno AL, Chung KJ, et al, “Prevention of Bacterial Endocarditis. Recommendations by the American Heart Association,” <i>JAMA</i>, 1990, 264(22):2919-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/2146414/pubmed" id="2146414" target="_blank">2146414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2136585">
<a name="2136585"></a>Di Lorenzo C, Lachman R, and Hyman PE, “Intravenous Erythromycin for Postpyloric Intubation,” <i>J Pediatr Gastroenterol Nutr</i>, 1990, 11(1):45-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/2136585/pubmed" id="2136585" target="_blank">2136585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3781679">
<a name="3781679"></a>Disse B, Gundert-Remy U, Weber E, Andrassy K, Sietzen W, Lang A. Pharmacokinetics of erythromycin in patients with different degrees of renal impairment. <i>Int J Clin Pharmacol Ther Toxicol.</i> 1986;24(9):460-464.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/3781679/pubmed" id="3781679" target="_blank">3781679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23768735">
<a name="23768735"></a>Donath E, Chaudhry A, Hernandez-Aya LF, Lit L. A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with chronic obstructive pulmonary disease. <i>Respir Med</i>. 2013;107(9):1385-1392. doi: 10.1016/j.rmed.2013.05.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/23768735/pubmed" id="23768735" target="_blank">23768735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drugs.1">
<a name="Drugs.1"></a>
<i>Drugs for Parasitic Infections</i>. The Medical Letter; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25687145">
<a name="25687145"></a>Eberly MD, Eide MB, Thompson JL, Nylund CM. Azithromycin in early infancy and pyloric stenosis. <i>Pediatrics</i>. 2015;135(3):483-488. doi:10.1542/peds.2014-2026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/25687145/pubmed" id="25687145" target="_blank">25687145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EES.1">
<a name="EES.1"></a>E.E.S. (erythromycin ethylsuccinate) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23637225">
<a name="23637225"></a>Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. <i>Pediatrics.</i> 2013;131(suppl 3):S163-S186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/23637225/pubmed" id="23637225" target="_blank">23637225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12960650">
<a name="12960650"></a>ElHennawy AA, Sparks JW, Armentrout D, Huseby V, Berseth CL. Erythromycin fails to improve feeding outcome in feeding-intolerant preterm infants. <i>J Pediatr Gastroenterol Nutr</i>. 2003;37(3):281-286. doi:10.1097/00005176-200309000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/12960650/pubmed" id="12960650" target="_blank">12960650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25806675">
<a name="25806675"></a>Ericson JE, Arnold C, Cheeseman J, et al. Use and safety of erythromycin and metoclopramide in hospitalized infants. <i>J Pediatr Gastroenterol Nutr</i>. 2015;61(3):334-339. doi:10.1097/MPG.0000000000000792<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/25806675/pubmed" id="25806675" target="_blank">25806675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7313575">
<a name="7313575"></a>Eriksson M, Bolme P, Blennow M. Absorption of erythromycin from pediatric suspension in infants and children. <i>Scand J Infect Dis</i>. 1981;13(3):211-215. doi:10.3109/inf.1981.13.issue-3.09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/7313575/pubmed" id="7313575" target="_blank">7313575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ery-Ped.1">
<a name="Ery-Ped.1"></a>Ery-Ped (erythromycin) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ery-Tab.1">
<a name="Ery-Tab.1"></a>Ery-Tab (erythromycin) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Erythrocin.1">
<a name="Erythrocin.1"></a>Erythrocin Lactobionate (erythromycin lactobionate) [prescribing information]. Lake Forest, IL: Hospira, Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Erythrocin.2">
<a name="Erythrocin.2"></a>Erythrocin Lactobionate (erythromycin lactobionate) [prescribing information]. Lenoir, NC: Exela Pharma Sciences, LLC; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Erythrocin.3">
<a name="Erythrocin.3"></a>Erythrocin I.V. (erythromycin lactobionate) [product monograph]. Brantford, Ontario, Canada: Methapharm Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Appco.1">
<a name="Appco.1"></a>Erythromycin [prescribing information]. Piscataway, NJ: Appco Pharma LLC; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arbor.1">
<a name="Arbor.1"></a>Erythromycin Base [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; July 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arbor.2">
<a name="Arbor.2"></a>Erythromycin delayed-release capsule [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ANI.1">
<a name="ANI.1"></a>Erythromycin ethylsuccinate suspension [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amneal.1">
<a name="Amneal.1"></a>Erythromycin ethylsuccinate suspension [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Methapharm.1">
<a name="Methapharm.1"></a>Erythromycin IV [product monograph]. Brantford, Ontario, Canada: Methapharm Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8018130">
<a name="8018130"></a>Farrar HC, Walsh-Sukys MC, Kyllonen K, Blumer JL. Cardiac toxicity associated with intravenous erythromycin lactobionate: two case reports and a review of the literature. <i>Pediatr Infect Dis J</i>. 1993;12(8):688-691.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/8018130/pubmed" id="8018130" target="_blank">8018130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31407456">
<a name="31407456"></a>Febo-Rodriguez L, Chumpitazi BP, Shulman RJ. Review article: childhood gastroparesis is a unique entity in need of further investigation. <i>Neurogastroenterol Motil</i>. 2020;32(3):e13699. doi:10.1111/nmo.13699<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/31407456/pubmed" id="31407456" target="_blank">31407456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12105828">
<a name="12105828"></a>Frossard JL, Spahr L, Queneau PE, et al. Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial [published correction appears in <i>Gastroenterology.</i> 2002;123(6):2162]. <i>Gastroenterology</i>. 2002;123(1):17-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/12105828/pubmed" id="12105828" target="_blank">12105828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2297290">
<a name="2297290"></a>Gholson CF and Warren GH, “Fulminant Hepatic Failure Associated With Intravenous Erythromycin Lactobionate,” <i>Arch Intern Med</i>, 1990, 150(1):215-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/2297290/pubmed" id="2297290" target="_blank">2297290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.2020">
<a name="GOLD.2020"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2022 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19366316">
<a name="19366316"></a>Goldstein LH, Berlin M, Tsur L, et al, "The Safety of Macrolides During Lactation," <i>Breastfeed Med</i>, 2009, 4(4):197-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/19366316/pubmed" id="19366316" target="_blank">19366316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Graber.1">
<a name="Graber.1"></a>Graber E. Acne vulgaris: overview of management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33567467">
<a name="33567467"></a>Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) guideline - update 2021. <i>Endoscopy</i>. 2021;53(3):300-332. doi:10.1055/a-1369-5274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/33567467/pubmed" id="33567467" target="_blank">33567467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2729328">
<a name="2729328"></a>Gumaste VV, “Erythromycin-Induced Pancreatitis,” <i>Am J Med</i>, 1989, 86(6 Pt 1):725.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/2729328/pubmed" id="2729328" target="_blank">2729328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7606309">
<a name="7606309"></a>Hanrahan JP, Choo PW, Carlson W, et al, “Terfenadine-Associated Ventricular Arrhythmias and QT<sub>c</sub> Interval Prolongation. A Retrospective Cohort Comparison With Other Antihistamines Among Members of a Health Maintenance Organization,” <i>Ann Epidemiol</i>, 1995, 5(3):201-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/7606309/pubmed" id="7606309" target="_blank">7606309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20881376">
<a name="20881376"></a>He ZY, Ou LM, Zhang JQ, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. <i>Respiration</i>. 2010;80(6):445-452. doi:10.1159/000321374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/20881376/pubmed" id="20881376" target="_blank">20881376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10609814">
<a name="10609814"></a>Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. <i>Lancet</i>. 1999;354(9196):2101-2105. doi:10.1016/s0140-6736(99)10073-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/10609814/pubmed" id="10609814" target="_blank">10609814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12237674">
<a name="12237674"></a>Hussain N, Herson VC. Erythromycin use during pregnancy in relation to pyloric stenosis. <i>Am J Obstet Gynecol</i>. 2002;187(3):821-822. doi:10.1067/mob.2002.126629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/12237674/pubmed" id="12237674" target="_blank">12237674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7151848">
<a name="7151848"></a>Iliopoulou A, Downey K, Chaput de Saintonge DM, Turner P. Should erythromycin dose be altered in haemodialysis patients? <i>Eur J Clin Pharmacol</i>. 1982;23(5):435-440. doi:10.1007/BF00605994<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/7151848/pubmed" id="7151848" target="_blank">7151848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2320062">
<a name="2320062"></a>Janssens J, Peeters TL, Vantrappen G, et al. Improvement of Gastric Emptying in Diabetic Gastroparesis by Erythromycin. <i>N Engl J Med</i>. 1990;322(15):1028-1031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/2320062/pubmed" id="2320062" target="_blank">2320062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3494560">
<a name="3494560"></a>Kanfer A, Stamatakis G, Torlotin JC, Fredj G, Kenouch S, Méry JP. Changes in erythromycin pharmacokinetics induced by renal failure. <i>Clin Nephrol.</i> 1987;27(3):147-150.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/3494560/pubmed" id="3494560" target="_blank">3494560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13218094">
<a name="13218094"></a>Kiefer L, Rubin A, McCoy JB, et al. The placental transfer of erythromycin. <i>Am J Obstet Gynecol</i>. 1955;69(1):174-177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/13218094/pubmed" id="13218094" target="_blank">13218094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11148514">
<a name="11148514"></a>Knight-Madden J, Serjeant GR. Invasive pneumococcal disease in homozygous sickle cell disease: Jamaican Experience 1973-1997. <i>J Pediatr.</i> 2001;138(1):65-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/11148514/pubmed" id="11148514" target="_blank">11148514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1435899">
<a name="1435899"></a>Koehler JE, Quinn FD, Berger TG, et al, “Isolation of Rochalimaea Species from Cutaneous and Osseous Lesions of Bacillary Angiomatosis,” <i>N Engl J Med</i>, 1992, 327(23):1625-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/1435899/pubmed" id="1435899" target="_blank">1435899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6860057">
<a name="6860057"></a>Kroboth PD, McNeil MA, Kreeger A, Dominguez J, Rault R. Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis. <i>Arch Intern Med.</i> 1983;143(6):1263-1265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/6860057/pubmed" id="6860057" target="_blank">6860057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14412751">
<a name="14412751"></a>Kunin CM, Finland M. Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin.<i> J Clin Invest.</i> 1959;38(9):1509-1519. doi:10.1172/JCI103929<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/14412751/pubmed" id="14412751" target="_blank">14412751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929377">
<a name="33929377"></a>Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. <i>Am J Gastroenterol</i>. 2021;116(5):899-917. doi:10.14309/ajg.0000000000001245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/33929377/pubmed" id="33929377" target="_blank">33929377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33251700">
<a name="33251700"></a>Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and treatment of lyme disease. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(1):1-9. doi:10.1002/acr.24495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/33251700/pubmed" id="33251700" target="_blank">33251700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14707025">
<a name="14707025"></a>Lau WC, Gurbel PA, Watkins PB, et al, “Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance,” <i> Circulation</i>, 2004, 109(2):166-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/14707025/pubmed" id="14707025" target="_blank">14707025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25859365">
<a name="25859365"></a>Ma TK, Chow KM, Choy AS, Kwan BC, Szeto CC, Li PK. Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients.<i> Clin Kidney J.</i> 2014;7(6):507-512. doi:10.1093/ckj/sfu098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/25859365/pubmed" id="25859365" target="_blank">25859365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18596312">
<a name="18596312"></a>MacLaren R, Kiser TH, Fish DN, et al, "Erythromycin vs Metoclopramide for Facilitating Gastric Emptying and Tolerance to Intragastric Nutrition in Critically Ill Patients," J<i>PEN J Parenter Enteral Nutr</i>, 2008, 32(4):412-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/18596312/pubmed" id="18596312" target="_blank">18596312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12591038">
<a name="12591038"></a>Maganti K, Onyemere K, and Jones MP, “Oral Erythromycin and Symptomatic Relief of Gastroparesis: A Systematic Review,” <i>Am J Gastroenterol</i>, 2003, 98(2):259-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/12591038/pubmed" id="12591038" target="_blank">12591038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17337692">
<a name="17337692"></a>Maheshwai N. Are young infants treated with erythromycin at risk for developing hypertrophic pyloric stenosis? <i>Arch Dis Child</i>. 2007;92(3):271-273. doi:10.1136/adc.2006.110007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/17337692/pubmed" id="17337692" target="_blank">17337692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21701222">
<a name="21701222"></a>Mansi Y, Abdelaziz N, Ezzeldin Z, Ibrahim R. Randomized controlled trial of a high dose of oral erythromycin for the treatment of feeding intolerance in preterm infants. <i>Neonatology</i>. 2011;100(3):290-294. doi:10.1159/000327536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/21701222/pubmed" id="21701222" target="_blank">21701222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-581516">
<a name="581516"></a>McCracken GH Jr, Ginsburg CM, Clahsen JC, Thomas ML. Pharmacologic evaluation of orally administered antibiotics in infants and children: effect of feeding on bioavailability. <i>Pediatrics</i>. 1978;62(5):738-743.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/581516/pubmed" id="581516" target="_blank">581516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nagata.1">
<a name="Nagata.1"></a>Nagata MJ, Tailor SAN. Erythromycin-induced ototoxicity: a case report and review of the literature.<i> Can J Hosp Pharm</i>. 2000;53(2):113-116. https://www.cjhp-online.ca/index.php/cjhp/article/download/710/841/2919. Accessed April 28, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18646077">
<a name="18646077"></a>Ng E, Shah VS. Erythromycin for the prevention and treatment of feeding intolerance in preterm infants. <i>Cochrane Database Syst Rev</i>. 2008;(3):CD001815. doi:10.1002/14651858.CD001815.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/18646077/pubmed" id="18646077" target="_blank">18646077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11320044">
<a name="11320044"></a>Ng PC, So KW, Fung KS, et al. Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2001;84(3):F177-F182. doi:10.1136/fn.84.3.f177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/11320044/pubmed" id="11320044" target="_blank">11320044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14581796">
<a name="14581796"></a>Ng SC, Gomez JM, Rajadurai VS, Saw SM, Quak SH. Establishing enteral feeding in preterm infants with feeding intolerance: a randomized controlled study of low-dose erythromycin. <i>J Pediatr Gastroenterol Nutr</i>. 2003;37(5):554-558. doi:10.1097/00005176-200311000-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/14581796/pubmed" id="14581796" target="_blank">14581796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22348492">
<a name="22348492"></a>Ng YY, Su PH, Chen JY, et al, "Efficacy of Intermediate-Dose Oral Erythromycin on Very Low Birth Weight Infants With Feeding Intolerance," <i>Pediatr Neonatol</i>, 2012, 53(1):34-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/22348492/pubmed" id="22348492" target="_blank">22348492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17205032">
<a name="17205032"></a>Nguyen NQ, Chapman MJ, Fraser RJ, et al, "Erythromycin Is More Effective Than Metoclopramide in the Treatment of Feed Intolerance in Critical Illness," <i>Crit Care Med</i>, 2007, 35(2):483-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/17205032/pubmed" id="17205032" target="_blank">17205032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17828038">
<a name="17828038"></a>Nguyen NQ, Chapman M, Fraser RJ, et al, "Prokinetic Therapy for Feed Intolerance in Critical Illness: One Drug or Two?" <i>Crit Care Med</i>, 2007, 35(11):2561-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/17828038/pubmed" id="17828038" target="_blank">17828038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16737869">
<a name="16737869"></a>Nuntnarumit P, Kiatchoosakun P, Tantiprapa W, Boonkasidecha S. Efficacy of oral erythromycin for treatment of feeding intolerance in preterm infants. <i>J Pediatr</i>. 2006;148(5):600-605. doi:10.1016/j.jpeds.2005.12.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/16737869/pubmed" id="16737869" target="_blank">16737869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11529540">
<a name="11529540"></a>Oei J and Lui K, "A Placebo-Controlled Trial of Low-Dose Erythromycin to Promote Feed Tolerance in Preterm Infants," <i>Acta Paediatr</i>, 2001, 90(8):904-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/11529540/pubmed" id="11529540" target="_blank">11529540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6975059">
<a name="6975059"></a>Patamasucon P, Kaojarern S, Kusmiesz H, Nelson JD. Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age. <i>Antimicrob Agents Chemother</i>. 1981;19(5):736-739. doi:10.1128/AAC.19.5.736<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/6975059/pubmed" id="6975059" target="_blank">6975059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15899929">
<a name="15899929"></a>Patole S, Rao S, Doherty D. Erythromycin as a prokinetic agent in preterm neonates: a systematic review. <i>Arch Dis Child Fetal Neonatal Ed.</i> 2005;90(4):F301-F306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/15899929/pubmed" id="15899929" target="_blank">15899929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1245094">
<a name="1245094"></a>Philipson A, Sabath LD, Charles D. Erythromycin and clindamycin absorption and elimination in pregnant women. <i>Clin Pharmacol Ther</i>. 1976;19(1):68-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/1245094/pubmed" id="1245094" target="_blank">1245094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15356306">
<a name="15356306"></a>Ray WA, Murray KT, Meredith S, et al, “Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes,” <i>N Engl J Med</i>, 2004, 351(11):1089-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/15356306/pubmed" id="15356306" target="_blank">15356306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22228004">
<a name="22228004"></a>Rodriguez L, Irani K, Jiang H, et al, "Clinical presentation, Response to Therapy, and outcome of Gastroparesis in Children," <i>J Pediatr Gastroenterol Nutr</i>, 2012, 55(2):185-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/22228004/pubmed" id="22228004" target="_blank">22228004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15155180">
<a name="15155180"></a>Rolain JM, Brouqui P, Koehler JE, et al. Recommendations for treatment of human infections caused by <i>Bartonella</i> species. <i>Antimicrob Agents Chemother.</i> 2004;48(6):1921-1933.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/15155180/pubmed" id="15155180" target="_blank">15155180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30159260">
<a name="30159260"></a>Saboute M, Mazouri A, NaimiDehnavi F, Khalesi N, Farahani Z. Influence of high-dose oral erythromycin on feeding intolerance in preterm neonates: A randomized controlled trial. <i>Med J Islam Repub Iran</i>. 2018;32:9. doi:10.18869/mjiri.32.9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/30159260/pubmed" id="30159260" target="_blank">30159260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879279">
<a name="23879279"></a>Sedlak T, Shufelt C, Iribarren C, et al, "Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval," <i>Ann Noninvasive Electrocardiol</i>, 2013, 18(4):389-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/23879279/pubmed" id="23879279" target="_blank">23879279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18723437">
<a name="18723437"></a>Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. <i>Am J Respir Crit Care Med</i>. 2008;178(11):1139-1147. doi:10.1164/rccm.200801-145OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/18723437/pubmed" id="18723437" target="_blank">18723437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30046644">
<a name="30046644"></a>Shirley DT, Farr L, Watanabe K, Moonah S. A review of the global burden, new diagnostics, and current therapeutics for amebiasis. <i>Open Forum Infect Dis</i>. 2018;5(7):ofy161. doi:10.1093/ofid/ofy161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/30046644/pubmed" id="30046644" target="_blank">30046644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8190550">
<a name="8190550"></a>Sims PJ, Waites KB, Crouse DT. Erythromycin lactobionate toxicity in preterm neonates.<i> Pediatr Infect Dis J</i>. 1994;13(2):164-167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/8190550/pubmed" id="8190550" target="_blank">8190550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sorensen.1">
<a name="Sorensen.1"></a>Sorensen HT, Skriver MV, Pedersen L, et al, "Risk of Infantile Hypertrophic Pyloric Stenosis After Maternal Postnatal Use of Macrolides," <i>Scand J Infect Dis</i>, 2003, 35(2):104-6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stang.1">
<a name="Stang.1"></a>Stang H, "Pyloric Stenosis Associated With Erythromycin Ingested Through Breastmilk," <i>Minn Med</i>, 1986, 69(11):669-70, 682.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Steigbigel.1">
<a name="Steigbigel.1"></a>Steigbigel NH. Macrolides and clindamycin. In: Mandell GL, Bennett JE, Dolin R, eds. <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases</i>. 5th ed. Philadelphia, PA: Churchill Livingstone; 2000:368-369.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3257783">
<a name="3257783"></a>Steketee RW, Wassilak SG, Adkins WN Jr, et al. Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled. <i>J Infect Dis</i>. 1988;157(3):434-440. doi:10.1093/infdis/157.3.434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/3257783/pubmed" id="3257783" target="_blank">3257783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34167901">
<a name="34167901"></a>Sukwuttichai P, Boonkasidecha S, Montakantikul P, Vimolsarawong N. Efficacy comparison between oral erythromycin versus domperidone for the treatment of feeding intolerance in preterm neonates. <i>Pediatr Neonatol</i>. 2021;62(5):543-549. doi:10.1016/j.pedneo.2021.05.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/34167901/pubmed" id="34167901" target="_blank">34167901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11555501">
<a name="11555501"></a>Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. <i>Chest</i>. 2001;120(3):730-733.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/11555501/pubmed" id="11555501" target="_blank">11555501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15794732">
<a name="15794732"></a>Tan AW, Tan HH. Acne vulgaris: a review of antibiotic therapy. <i>Expert Opin Pharmacother</i>. 2005;6(3):409-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/15794732/pubmed" id="15794732" target="_blank">15794732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12688836">
<a name="12688836"></a>Tan HH. Antibacterial therapy for acne: a guide to selection and use of systemic agents. <i>Am J Clin Dermatol</i>. 2003;4(5):307-314.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/12688836/pubmed" id="12688836" target="_blank">12688836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8430982">
<a name="8430982"></a>Tappero JW, Koehler JE, Berger TG, et al, “Bacillary Angiomatosis and Bacillary Splenitis in Immunocompetent Adults,” <i>Ann Int Med</i>, 1993, 118(5):363-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/8430982/pubmed" id="8430982" target="_blank">8430982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6117714">
<a name="6117714"></a>Taylor R, Schofield IS, Ramos JM, Bint AJ, Ward MK. Ototoxicity of erythromycin in peritoneal dialysis patients. <i>Lancet</i>. 1981;2(8252):935-936.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/6117714/pubmed" id="6117714" target="_blank">6117714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6969579">
<a name="6969579"></a>Thompson PJ, Burgess KR, Marlin GE. Influence of food on absorption of erythromycin ethyl succinate. <i>Antimicrob Agents Chemother</i>. 1980;18(5): 829-831.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/6969579/pubmed" id="6969579" target="_blank">6969579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27199619">
<a name="27199619"></a>Tillman EM, Smetana KS, Bantu L, Buckley MG. Pharmacologic treatment for pediatric gastroparesis: A review of the literature. <i>J Pediatr Pharmacol Ther</i>. 2016;21(2):120-132. doi:10.5863/1551-6776-21.2.120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/27199619/pubmed" id="27199619" target="_blank">27199619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16340941">
<a name="16340941"></a>Tiwari T, Murphy TV, Moran J. Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines. <i>MMWR.</i> 2005;54(RR-14):1-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/16340941/pubmed" id="16340941" target="_blank">16340941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2020">
<a name="HHS.2020"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Updated February 17, 2022. Accessed January 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8036045">
<a name="8036045"></a>Waites KB, Sims PJ, Crouse DT, et al. Serum concentrations of erythromycin after intravenous infusion in preterm neonates treated for <i>Ureaplasma urealyticum</i> Infection. <i>Pediatr Infect Dis J.</i> 1994;13(4):287-293.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/8036045/pubmed" id="8036045" target="_blank">8036045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update. <i>Perit Dial Int.</i> 2012;32(suppl 2):S32-S86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22314391">
<a name="22314391"></a>Waseem S, Islam S, Kahn G, et al, "Spectrum of Gastroparesis in Children," <i>J Pediatr Gastroenterol Nutr</i>, 2012, 55(2):166-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/22314391/pubmed" id="22314391" target="_blank">22314391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28889106">
<a name="28889106"></a>Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>Eur Respir J</i>. 2017;50(3). pii: 1602265. doi: 10.1183/13993003.02265-2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/28889106/pubmed" id="28889106" target="_blank">28889106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-671237">
<a name="671237"></a>Welling PG, Craig WA. Pharmacokinetics of intravenous erythromycin. <i>J Pharm Sci.</i> 1978;67(8):1057-1059. doi:10.1002/jps.2600670809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/671237/pubmed" id="671237" target="_blank">671237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23973659">
<a name="23973659"></a>Wilson R, Sethi S, Anzueto A, Miravitlles M. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. <i>J Infect</i>. 2013;67(6):497-515. doi: 10.1016/j.jinf.2013.08.010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/23973659/pubmed" id="23973659" target="_blank">23973659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17029130">
<a name="17029130"></a>Wormser GP, Dattwyler RJ, Shapiro ED, et al, “The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,” <i>Clin Infect Dis</i>, 2006, 43(9):1089-134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/17029130/pubmed" id="17029130" target="_blank">17029130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7489869">
<a name="7489869"></a>Wynn RL and Bergman SA, “Antibiotics and Their Use in the Treatment of Orofacial Infections, Part I and Part II,” <i>Gen Dent</i>, 1994, 42(5):398-402, 498-502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/7489869/pubmed" id="7489869" target="_blank">7489869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1813347">
<a name="1813347"></a>Wynn RL, "Current Concepts of the Erythromycins," <i>Gen Dent</i>, 1991, 39(6):408, 410-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/1813347/pubmed" id="1813347" target="_blank">1813347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897386">
<a name="26897386"></a>Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. <i>J Am Acad Dermatol. </i>2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. Accessed March 3, 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/26897386/pubmed" id="26897386" target="_blank">26897386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20413982">
<a name="20413982"></a>Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. <i>Int Arch Allergy Immunol</i>. 2010;153(2):152-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/20413982/pubmed" id="20413982" target="_blank">20413982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30007329">
<a name="30007329"></a>Zikic A, Schünemann H, Wi T, Lincetto O, Broutet N, Santesso N. Treatment of neonatal chlamydial conjunctivitis: a systematic review and meta-analysis. <i>J Pediatric Infect Dis Soc</i>. 2018;7(3):e107-e115. doi:10.1093/jpids/piy060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-systemic-drug-information/abstract-text/30007329/pubmed" id="30007329" target="_blank">30007329</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9118 Version 637.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
